Tag Archive

Lifestyle Changes to help Reduce the Risk of Dementia

Understanding the risk factors for dementia, including lifestyle choices and health conditions, is crucial in preventing cognitive decline. Dr Emer MacSweeney, CEO, Medical Director and Consultant Neuroradiologist […]

Understanding ARIA – a recognised side-effect of new Alzheimer’s medications

ARIA, or Amyloid-Related Imaging Abnormalities, is a recognised side-effect of lecanemab (Lequembi™) and donanemab and other medications in the same class. These medications are monoclonal antibodies (MABs) […]

Understanding Lecanemab (Leqembi™): A Breakthrough in Alzheimer’s Treatment

Lecanemab, also known by its name Leqembi™, represents a significant milestone in the ongoing battle against Alzheimer’s disease. This innovative drug offers new hope to patients living […]

Giving Hope Through Clinical Trials – David’s Story

David was diagnosed with Alzheimer’s in 2016 after experiencing problems with his memory. Below he shares his story about joining the Clarity clinical trial at Re:Cognition Health, […]

A New Milestone in Alzheimer’s Treatment: MHRA Approves Lecanemab (Leqembi™)

PRESS RELEASE. Re:Cognition Health is delighted to offer this new treatment Re:Cognition Health is delighted with the announcement that the MHRA has approved Lecanemab, a pioneering treatment […]